Results 271 to 280 of about 445,727 (296)

Interleukin-33

2014
Sangmin Jeong, Soohyun Kim
openaire   +1 more source

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Lancet, The, 2008
Andrea Rubbert-Roth, César R Ramos-Remus, Rieke E Alten   +2 more
exaly  

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Lancet, The, 2013
Antoinette Moran, Linda A Dimeglio, Stephen E Gitelman   +2 more
exaly  

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2015
Iain B Mcinnes, Philip J Mease, Bruce W Kirkham   +2 more
exaly  

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Lancet, The, 2017
B G Feagan, Julian Panes, Arthur Kaser
exaly  

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

Lancet, The, 2012
Daniel F Freitag, John Gregson, Peter Willeit   +2 more
exaly  

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Nature Reviews Drug Discovery, 2012
Charles A Dinarello, Anna Simon, Jos W M Van Der Meer   +2 more
exaly  

C31. INTERLEUKIN-33 BIOLOGY

2011
openaire   +1 more source

Platelets Constitutively Express Interleukin-33 Protein

Journal of Allergy and Clinical Immunology, 2014
Tomohiro Takeda, Hirotoshi Unno, Hideaki Morita, Hirohisa Saito, Kenji Matsumoto, Akio Matsuda   +5 more
openaire   +1 more source

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Lancet, The, 2012
Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker   +2 more
exaly